HomeCompareKAEPY vs PFE

KAEPY vs PFE: Dividend Comparison 2026

KAEPY yields 2.34% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $26.0K in total portfolio value· pulled ahead in Year 9
10 years
KAEPY
KAEPY
● Live price
2.34%
Share price
$8.54
Annual div
$0.20
5Y div CAGR
2.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.6K
Annual income
$340.30
Full KAEPY calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — KAEPY vs PFE

📍 PFE pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodKAEPYPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, KAEPY + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
KAEPY pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KAEPY
Annual income on $10K today (after 15% tax)
$198.97/yr
After 10yr DRIP, annual income (after tax)
$289.26/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $22,030.65/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KAEPY + PFE for your $10,000?

KAEPY: 50%PFE: 50%
100% PFE50/50100% KAEPY
Portfolio after 10yr
$36.6K
Annual income
$13,299.51/yr
Blended yield
36.37%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

KAEPY
No analyst data
Altman Z
1.2
Piotroski
4/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KAEPY buys
0
PFE buys
0
No recent congressional trades found for KAEPY or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricKAEPYPFE
Forward yield2.34%6.13%
Annual dividend / share$0.20$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR2.1%13.2%
Portfolio after 10y$23.6K$49.6K
Annual income after 10y$340.30$26,258.71
Total dividends collected$2.9K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: KAEPY vs PFE ($10,000, DRIP)

YearKAEPY PortfolioKAEPY Income/yrPFE PortfolioPFE Income/yrGap
1$10,939$239.00$9,153$693.39+$1.8KKAEPY
2$11,954$249.47$8,593$849.25+$3.4KKAEPY
3$13,051$260.14$8,336$1,066.78+$4.7KKAEPY
4$14,236$271.01$8,437$1,384.80+$5.8KKAEPY
5$15,514$282.07$9,013$1,875.40+$6.5KKAEPY
6$16,894$293.32$10,306$2,680.72+$6.6KKAEPY
7$18,381$304.77$12,820$4,101.38+$5.6KKAEPY
8$19,984$316.42$17,673$6,826.70+$2.3KKAEPY
9← crossover$21,711$328.26$27,543$12,591.86$5.8KPFE
10$23,571$340.30$49,560$26,258.71$26.0KPFE

KAEPY vs PFE: Complete Analysis 2026

KAEPYStock

The Kansai Electric Power Company, Incorporated engages in electricity, gas and heat supply, and telecommunication businesses in Japan. It operates through four segments: Energy Business, Power Transmission and Distribution Business, Information and Communication Business, and Life and Business Solution Business. The company generates power from thermal, hydropower, wind, biomass, and nuclear power generation plants. It is also involved in the power transmission and distribution business; provision of information and communication services for homes and businesses under the eo Hikari brand; mobile business under the mineo business; corporate solution business; and real estate leasing, sale, and management activities; and leisure, leasing, call center management, dispatching, medical health care, and home security businesses. In addition, the company engages in the maintenance and construction of power distribution and electricity lines, thermal and nuclear power generation facilities, and information and communication equipment; utility pole advertising; manufacture, supply, and sale of gas; manufacture and sale of power distribution equipment, such as overhead wire hardware, insulators/bushings, steel pipe columns, concrete columns, etc.; housing equipment sales; remodeling work; and passenger/freight transportation. Further, it is involved in the survey and research on safety technology for nuclear power generation, survey/design /construction supervision related to civil engineering/architecture, etc.; acceptance/ storage/vaporization /delivery of LNG; condominium high-voltage batch power reception service business; fuel trading and transportation; corporate settlement; and provision of survey, analysis, consulting, and construction services related to the environment, civil engineering, and architecture, as well as public relations and engineering services The Kansai Electric Power Company, Incorporated was founded in 1951 and is headquartered in Osaka, Japan.

Full KAEPY Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this KAEPY vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KAEPY vs SCHDKAEPY vs JEPIKAEPY vs OKAEPY vs KOKAEPY vs MAINKAEPY vs JNJKAEPY vs MRKKAEPY vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.